gilenya
FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis
December 6, 2019Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma
The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …
A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis
July 19, 2019Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma
Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …
FDA awards first paediatric MS approval to Novartis’ Gilenya
May 14, 2018Sales and Marketing FDA, gilenya, multiple sclerosis, pharma
The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) …
Novartis celebrates success of Gilenya in paediatric multiple sclerosis
September 5, 2017Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals
Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …
EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
Novartis MS drug scores positive late-stage trial result
April 21, 2015Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis
People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …
Novartis to highlight Gilenya data at neurology congress
April 13, 2015Sales and Marketing American Academy of Neurology, Novartis, fingolimod, gilenya
Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …
NICE final ‘yes’ for Biogen’s MS pill
August 27, 2014Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya
In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
Sales rise for Novartis
January 30, 2014Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales
Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …
NICE recommends Aubagio
January 22, 2014Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya
NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …
Strong sales for Biogen Idec’s MS drug
October 29, 2013Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera
Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Sanofi’s Lemtrada given European go ahead
September 18, 2013Research and Development, Sales and Marketing Aubagio, Lemtrada, MS, Sanofi, gilenya
Latest content
FibroFind appoints Lee Borthwick as CEO
